An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo
in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN)
after a 16 week treatment period.